Nanomedicine market poised for double-digit growth

It is driven by the rising prevalence of chronic diseases.

The global nanomedicine market is projected to more than double over the next decade, rising to $554b by 2034 from $227b in 2025, with an estimated compound annual growth rate of around 10% between 2026 and 2034, according to DelveInsight.

The report said the growth will be driven by the rising prevalence of chronic diseases, including cancer, cardiovascular disorders, neurodegenerative conditions, and diabetes, which are increasing demand for advanced diagnostic and therapeutic solutions.

Continuous advancements in nanotechnology, such as nanoparticles, nanocarriers, nanosensors, and nano-enabled drug delivery systems, are expanding the applications and effectiveness of nanomedicine, whilst targeted drug delivery improves drug bioavailability, reduces side effects, and enhances precision, particularly in oncology, immunotherapy, and gene therapy.

Investment in research and development by pharmaceutical companies, biotech firms, and academic institutions is accelerating the development of next-generation nanotherapeutics and diagnostics.

Nanoparticles and nano-based tools are also strengthening the diagnostic segment by enabling early disease detection, high-sensitivity imaging, and improved biosensing.

The market is further supported by the rise of personalised medicine, regulatory approvals for nano-formulations, collaborations between pharmaceutical companies and nanotech startups, and emerging technologies in nanorobotics and nano-engineering, which offer new possibilities in targeted therapy, precision surgery, and cellular repair.

The Asia-Pacific region is becoming a major growth hub, driven by increasing healthcare needs, rising rates of cancer, cardiovascular conditions, and infectious diseases, expanding biotech research, favorable regulatory changes, and greater investments in advanced therapeutic technologies.

Collaborations between regional biotech companies and global pharmaceutical firms are accelerating technology transfer and facilitating broader clinical evaluation of nanomedicines, supporting the region’s growing role in the global market.